by Michael Fossel

Received: 20 March 2018;  Published: 28 March 2018;  doi: 10.21926/obm.geriatr.1801004

All of us are intuitively aware, and many of us explicitly aware as well, of the meaning of geriatrics as a specialty. After all, most of us practice geriatrics or we have been intimately involved with this area and we are know the reality of geriatrics. Or do we? Geriatrics is an oddly ill-defined specialty when you look at it more carefully. Some of us practice medicine, some of us practice in the social sciences, and many of us simply do our jobs day-to-day and try to get by. What we share, however, is the heart [...]

by Michael Fossel

Received: 12 December 2017;  Published: 24 December 2017;  doi: 10.21926/obm.geriatr.1704003

by Giacinto Libertini

Received: 19 February 2017;  Published: 13 April 2017;  doi: 10.21926/obm.geriatr.1702002

Currently, geriatric medicine consists mainly of palliative treatment of the disorders that characterize senile decay. This is perfectly compatible with the prevailing view that aging is the inevitable result of multiple degenerative processes that cannot be treated effectively as they are, in themselves, inevitable and irreversible. This interpretation of aging clashes with a mass of data and arguments that, conversely, indicate that aging is a specific physiological function, favoured by supra-individual natural [...]

by Michael Fossel

Received: 11 December 2016;  Published: 06 January 2017;  doi: 10.21926/obm.geriatr.1701001

Geriatrics, and much of clinical medicine, is on the verge of a profound transformational shift. Until now, there has been a sharp conceptual divide between diseases which can be readily and effectively treated, and diseases which we have thought to be beyond clinical intervention. In the first disease category, are many of the most common infections that respond to antibiotics and immunizations. We have made dramatic changes in the demographics and the mortality of many such treatable diseases. At the other extrem [...]

by Stephanie Liana  , Ferdy Kurniawan Cayami  , Annang Giri Moelyo  , Ratna Dewi Artati  , Muhammad Faizi  , Nur Rochmah  , Rusdi Andid  , Yulisnawati Hasanah  , Aditiawati  and Agustini Utari

Received: 22 January 2026;  Published: 02 June 2026;  doi: 10.21926/obm.genet.2602344

Osteogenesis Imperfecta (OI) is a rare genetic disorder caused by mutations in genes that encode collagen, with varying clinical presentations. While some studies in Indonesia have reported OI’s clinical features and treatments, there is a lack of comprehensive national data, with limited awareness and access to specialized care for affected individuals. This collaborative study, involving multiple centres across Indonesia, aims to address data fragmentation by analyzing patient characteristics, clinical manifestat [...]

by Mahmood Shams  , Nader Safarian  , Samila Farokhimanesh  and Akbar Dorgalaleh

Received: 23 January 2026;  Published: 26 May 2026;  doi: 10.21926/obm.genet.2602343

Congenital factor VII (FVII) deficiency is the most common rare bleeding disorder (RBD), presenting with various clinical manifestations. Given the heightened risk of life-threatening bleeding and fatal hemorrhagic complications, prompt detection of the disorder is critical, especially in cases with low FVII levels and a history of familial severe clinical presentations. In such cases, prenatal diagnosis (PND) emerges as a life-saving option. In this study, we reported two PNDs in a family with a positive family hi [...]

by José A. Cedeño-Escudero  , Luis A. Sotillo-Bent  , Evelyn Medina-Batista  and Luis A. Méndez-Rosado

Received: 26 January 2026;  Published: 20 May 2026;  doi: 10.21926/obm.genet.2602342

Hereditary Cardiomyopathies (HCs) are defined as genetically determined cardiovascular diseases (CVDs) that frequently exhibit a familial inheritance pattern. These conditions include cardiomyopathies (CMs), arrhythmias (ARs), and other inherited cardiovascular syndromes. In Panama, the national incidence of Hereditary Cardiomyopathies remains unknown. The objective was to identify genetic variants in Panamanian patients diagnosed with HCs or cardiac arrhythmias and subsequently to identify carrier families to prov [...]

by Hicham Bouchahta  , Nada Benyahya  , Zhour EL Amrani  , Fatima Ouboukss  , Thomas Liehr  , Siham Chafai Elalaoui  , Isabel Marques Carreira  , Yassamine Doubaj  , Abdelhafid Natiq  and Laila Sbabou

Received: 06 February 2026;  Published: 19 May 2026;  doi: 10.21926/obm.genet.2602341

Isolated duplications of the long arm of chromosome 3 (3q) are rare chromosomal abnormalities. To date, approximately 32 pure cases have been documented. Most reported 3q duplications arise from unbalanced translocations or inversion-loops mechanisms and are associated with additional chromosomal imbalances, making pure duplications particularly valuable for genotype-phenotype correlations. We report a 17-year-old female with a de novo pure tandem duplication of 3q26.33-q28 (~10.945 Mb). The clinical course was mar [...]

by Manal Hadi Ghaffoori Kanaan  , Ahmad M. Tarek  , Beom-Jin Lee  , Sura Saad Abdullah  , Chulhun Park  , Abdolmajid Ghasemian  and Steward Mudenda

Received: 14 March 2026;  Published: 18 May 2026;  doi: 10.21926/obm.genet.2602340

Acute myeloid leukemia (AML) is a heterogeneous hematologic malignancy with genetic and clinical characteristics. Recent advances in multi-omic technologies, including genomics, epigenomics, transcriptomics, proteomics, metabolomics, immunomics, microbiome profiling, and both spatial and single-cell analyses, have greatly enhanced our understanding of AML pathobiology. Substantial multi-omic studies show that recurrent driver mutations not only impart traditional genomic lesions but also participate in chromatin re [...]

by Havva Özgen Eyüpoğlu  , Hüseyin Çağsın  and Nedime Serakıncı

Received: 12 December 2025;  Published: 13 May 2026;  doi: 10.21926/obm.genet.2602339

Cancer remains one of the major global challenges due to its complex and heterogeneous molecular nature across individuals. Recent advances in technology have enhanced the understanding of cancer’s molecular mechanisms, paving the way for the development of effective therapeutics. These include small-molecule inhibitors and monoclonal antibodies, used to interfere with the oncogenic signaling pathways. Immunotherapy has also emerged as a promising area in cancer therapy, with approaches such as immune checkpoint in [...]